ライフサイエンスコーパス: azathioprine

1 receiving infliximab,and 1 patient receiving azathioprine).

2 i.e. rituximab, belimumab, mycophenolate and azathioprine).

3 ent (116 to mycophenolate mofetil and 111 to azathioprine).

4 of a subsequent NMOSD relapse compared with azathioprine.

5 , especially in those who are not commencing azathioprine.

6 mission at month 28 with rituximab than with azathioprine.

7 gs were mycophenolate mofetil, sirolimus, or azathioprine.

8 es within 2 weeks of starting treatment with azathioprine.

9 ond-line treatments such as methotrexate and azathioprine.

10 travenous cyclophosphamide and equivalent to azathioprine.

11 ethnicity, thrombocytopenia, and the use of azathioprine.

12 his effect can be negated by the addition of azathioprine.

13 its safety and tolerability in comparison to azathioprine.

14 hen compared with those receiving placebo or azathioprine.

15 ed corticosteroids, oral corticosteroids and azathioprine.

16 tocilizumab and 59 were randomly assigned to azathioprine.

17 d lastly to both weekly adalimumab and daily azathioprine.

18 ne (6-TP) prodrugs include 6-thioguanine and azathioprine.

19 th heterozygous range TPMT activity received azathioprine 1.0 mg/kg daily, compared with 2.5 mg/kg da

20 clophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group).

21 e-only group required immunosuppression with azathioprine (17% vs. 48%, P<0.001) or were hospitalized

22 nd 14 plus daily oral placebo capsules; oral azathioprine 2.5 mg/kg daily plus placebo infusions on t

23 mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per kilogram of body weight per day),

24 ral combination of danazol (10-15 mg/kg) and azathioprine (2 mg/kg) was given to 18 of the 35 patient

25 tocilizumab (8 mg/kg every 4 weeks) or oral azathioprine (2-3 mg/kg per day) by an independent stati

26 ients were randomly assigned to groups given azathioprine (2.5 mg . kg(-1) . day(-1), n = 68) or plac

27 ers were randomly assigned to treatment with azathioprine (2.5 mg kg(-1) day(-1), n = 65) or conventi

28 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine (30.9%), and anti-TNFs (30.9%) were the mos

29 lavulanate (21 of 96; 22%), diclofenac (6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (

30 in the first 90 days following initiation of azathioprine, 40 acute pancreatitis events occurred (inc

31 weeks of treatment, 30 patients treated with azathioprine (44.1%) and 23 given placebo (36.5%) were i

32 limited ANCA-associated vasculitis) received azathioprine (58 patients) or rituximab (57 patients).

33 The immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are c

34 5 and on CIST (steroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) we

35 corticosteroids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5)

36 ed 5-aminosalicylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

37 e metabolism of their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulind

38 and all prescriptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were

39 lled trials (N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, c

40 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotic

41 xposed or not exposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during

42 costeroids, and 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

43 d infliximab + azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95%

44 000; 95% CI, 4-24), 1 of 133 patients taking azathioprine (752 of 100,000; 95% CI, 205-1914), 1 of 14

45 s predicted to be therapeutic for IF/TA were azathioprine, a drug to prevent acute rejection in renal

46 Azathioprine, a purine antimetabolite immunosuppressant,

47 Azathioprine, a widely used immunosuppressant, is also u

48 of infliximab and azathioprine (infliximab + azathioprine), adalimumab, and vedolizumab were superior

49 ncer subgroups between users and nonusers of azathioprine, adjusting for propensity scores.

50 r a Sweetlike presentation in the setting of azathioprine administration is azathioprine hypersensiti

51 lone(P =.017) and 23.7% (18 of 76) receiving azathioprine alone(P =.032).

52 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective i

53 Azathioprine and 6-mercaptopurine are the standard maint

54 The thiopurines azathioprine and 6-mercaptopurine have been extensively

55 Studies of azathioprine and 6-mercaptopurine metabolites will make

56 The prodrugs azathioprine and 6-mercaptopurine, which are well-establ

57 of treatment, and total therapeutic dose of azathioprine and 6-MP.

58 inhibitor and statin, 378 (9.2%) were taking azathioprine and an angiotensin-converting enzyme inhibi

59 Azathioprine and corticosteroids were discussed as poten

60 t with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked r

61 olone sodium succinate, plasma exchange, and azathioprine and has remained in remission.

62 ies have shown an association between use of azathioprine and increased risk of acute pancreatitis in

63 Combination therapy with azathioprine and infliximab for ulcerative colitis has n

64 t risk of hepatotoxicity was associated with azathioprine and infliximab, but the actual number of ca

65 Azathioprine and its metabolite 6-mercaptopurine (6-MP)

66 (Evaluating the Effectiveness of Prednisone, Azathioprine and N-Acetylcysteine in Patients with IPF)

67 ng cyclosporine A, mycophenolate mofetil, or azathioprine and prednisone).

68 These findings demonstrate that azathioprine and related compounds could be potent antim

69 patients with active disease who have failed azathioprine and rituximab.

70 Among these, the immunosuppressant azathioprine and the fluoroquinolone antibiotics ciprofl

71 receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone;

72 given triple immunosuppression (tacrolimus, azathioprine, and corticosteroids), which was continued

73 ed of thymoglobulin, maintenance prednisone, azathioprine, and CsA.

74 ions, such as corticosteroids, methotrexate, azathioprine, and cyclophosphamide.

75 evidence favors the use of corticosteroids, azathioprine, and mycophenolate mofetil in ocular myasth

76 A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely

77 fibrosis in a clinical trial of prednisone, azathioprine, and N-acetylcysteine underwent HRCT at stu

78 ps -- receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone,

79 re treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo.

80 steroids, vitamin D analogues, fluorouracil, azathioprine, and oral prednisolone with improved outcom

81 osuppressive regimen including cyclosporine, azathioprine, and prednisolone.

82 ed PML after treatment with corticosteroids, azathioprine, and rituximab.

83 one noting no increased risk of cancer with azathioprine, another suggesting that anti-tumor necrosi

84 cribed any ISDs (cyclosporine, methotrexate, azathioprine, anti-TNF drugs, or others).

85 overlap syndromes, whereas mycophenolate and azathioprine are also used for both skin and lung diseas

86 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective anticancer agents with remark

87 k meta-analysis, adalimumab and infliximab + azathioprine are the most effective therapies for induct

88 ugs (i.e., thioguanine [TG], mercaptopurine, azathioprine) are commonly used for the treatment of can

89 immunosuppressants (e.g., cyclophosphamide, azathioprine) are eventually required in most cases.

90 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed anticancer agents and

91 ercaptopurine (MP), 6-thioguanine ((S)G) and azathioprine, are widely used for the treatment of many

92 We believe the study of azathioprine as systemic monotherapy for atopic eczema h

93 e aimed to assess the safety and efficacy of azathioprine as systemic monotherapy for moderate-to-sev

94 Treatment with azathioprine as systemic monotherapy produces clinically

95 Azathioprine (AZA) and tissue necrosis factor-alpha-inhi

96 is associated with less acute rejection than azathioprine (AZA) early after kidney transplantation.

97 ferior to cyclophosphamide (CYC) followed by azathioprine (AZA) for remission-induction in severe ANC

98 s against acute rejection when compared with azathioprine (AZA) in heart and renal transplantation.

99 Azathioprine (AZA) is used to maintain remission in auto

100 We suggest that immunosuppression by azathioprine (Aza) may be one such treatment.

101 mmatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse

102 blood and tissue from CD patients receiving azathioprine (AZA) therapy, and posttreatment Vdelta2 T

103 nous (IV) cyclophosphamide (CYC) followed by azathioprine (AZA) treatment in pulmonary fibrosis in SS

104 ndomized, and controlled trial comparing CsA/azathioprine (Aza) versus Tac/MMF in 289 kidney transpla

105 rial evidence was identified for apremilast, azathioprine (AZA), baricitinib, ciclosporin A (CSA), co

106 proach includes the use of immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newe

107 ere withdrawn from a regimen of steroids and azathioprine (AZA).

108 odes after renal transplantation compared to azathioprine (Aza).

109 tion signal inhibitor everolimus compared to azathioprine (AZA).

110 ic mycophenolic acid should be replaced with azathioprine before conception.

111 A second-line treatment option is azathioprine, but efficacy is lower, and evidence is wea

112 Unlicensed treatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline

113 t) improvement in mean disease activity with azathioprine compared with a 20% (6.6 unit) improvement

114 (49 of 78) of patients receiving infliximab/azathioprine, compared with 54.6% (42 of 77) receiving i

115 (31 of 78) of patients receiving infliximab/azathioprine,compared with 22.1% (17 of 77) receiving in

116 We therefore hypothesized that azathioprine could also inhibit Vav1 in pancreatic tumor

117 xic immunosuppressive agents other than MTX (azathioprine, cyclosporine, and leflunomide) were also a

118 ) by using TPMT enzyme activity to establish azathioprine dose.

119 rst 4 weeks, all participants received lower azathioprine doses (0.5 and 1.0 mg/kg daily, respectivel

120 caps compiled prospective data files on the azathioprine dosing patterns of 180 adult renal transpla

121 allow clarification of the relation between azathioprine effectiveness and metabolite profiles in ot

122 We identified 3574 azathioprine episodes and 18 700 no-use episodes, which

123 Among the matched azathioprine episodes, mean age was 14.3 years (SD 3.1),

124 oliferative therapy use at our center (early azathioprine era: 1990-2000 vs modern mycophenolate era:

125 ersely, nonbiologic combination therapy with azathioprine exhibited the highest DR owing to ADRs.

126 icantly increased risk of SCC in relation to azathioprine exposure (1.56, 95% confidence interval [CI

127 In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk

128 e administered for 3 to 6 months followed by azathioprine for 12 to 15 months.

129 ycophenolate mofetil was less effective than azathioprine for maintaining disease remission.

130 olled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed

131 mycophenolate mofetil is more effective than azathioprine for preventing relapses in AAV.

132 ly results suggest that MMF is equivalent to azathioprine for remission maintenance, although large r

133 nce--via oral delivery of cyclosporine A and azathioprine for two months at the time of initiation of

134 tudy found great success in transitioning to azathioprine from mycophenolate mofetil prior to pregnan

135 dverse events occurred in 14 patients in the azathioprine group (20.6%) and 7 in the placebo group (1

136 r relapse had occurred in 17 patients in the azathioprine group (29%) and in 3 patients in the rituxi

137 til group (42/76 patients) compared with the azathioprine group (30/80 patients), with an unadjusted

138 lso longer in the tocilizumab group than the azathioprine group (67.2 weeks [IQR 47.9-77.9] vs 38.0 [

139 was longer in the tocilizumab group than the azathioprine group (78.9 weeks [IQR 58.3-90.6] vs 56.7 [

140 tocilizumab group had a relapse than in the azathioprine group (five [20%] of 25 patients vs 15 [68%

141 s, and cancer developed in 2 patients in the azathioprine group and 1 in the rituximab group.

142 Eight patients in the azathioprine group and 11 in the rituximab group had sev

143 adverse events; there were 44 events in the azathioprine group and 45 in the rituximab group.

144 events occurred in 33.3% of patients in the azathioprine group and in 23.5% of those in the mycophen

145 e adverse events in 13 patients (16%) in the azathioprine group and there were 8 severe adverse event

146 compared with 29 (56%) of 52 patients in the azathioprine group at the end of the study (HR 0.188 [95

147 Two patients in the azathioprine group died (1 from sepsis and 1 from pancre

148 mab group and 28 (47%) of 59 patients in the azathioprine group had a relapse at the end of the study

149 A larger percentage of patients in the azathioprine group had adverse events that led to study

150 mab group and 56 (95%) of 59 patients in the azathioprine group had adverse events.

151 mab group and 13 (35%) of 37 patients in the azathioprine group had relapsed by the end of the study.

152 core >220, showed lower relapse rates in the azathioprine group than in the placebo group (11.8% vs 3

153 her cumulative proportion of patients in the azathioprine group were free of perianal surgery than in

154 3-year follow-up period, 16 patients in the azathioprine group were switched to mercaptopurine or me

155 s (56 in the tocilizumab group and 52 in the azathioprine group).

156 In the azathioprine group, a median 67% of trimesters were spen

157 in the tocilizumab group and one (2%) in the azathioprine group, but neither of the deaths were treat

158 53% of the patients in the cyclophosphamide-azathioprine group, had a complete remission by 6 months

159 e mofetil group and 32.4% (36 of 111) in the azathioprine group.

160 m the placebo group and seven (11%) from the azathioprine group.

161 cocorticoid and cyclophosphamide followed by azathioprine, has improved the disease prognosis.

162 Although calcineurin inhibitors and azathioprine have been linked with posttransplant malign

163 ated with antimetabolites (mycophenolate and azathioprine) have a lower risk of PTLD than those witho

164 We report a case of azathioprine hypersensitivity syndrome and review the li

165 Histologically, both azathioprine hypersensitivity syndrome and Sweet syndrom

166 Azathioprine hypersensitivity syndrome can present clini

167 Azathioprine hypersensitivity syndrome seems to be a neu

168 he setting of azathioprine administration is azathioprine hypersensitivity syndrome.

169 %), cyclosporine in 98 patients (74.2%), and azathioprine in 65 patients (49.2%).

170 In addition, MMF was shown to be superior to azathioprine in decreasing the incidence of treatment fa

171 Mycophenolate mofetil was superior to azathioprine in maintaining a renal response to treatmen

172 e the safety and efficacy of tocilizumab and azathioprine in patients with highly relapsing NMOSD.

173 uppression with cyclophosphamide followed by azathioprine in patients with severe (organ-threatening)

174 eterozygous range TPMT activity responded to azathioprine in similar proportions to other participant

175 ls has implications for the long-term use of azathioprine in the management of inflammatory disorders

176 ory bowel disease (of whom, 5,197 (11%) used azathioprine) in Denmark from 1997 to 2008.

177 oliferative agents (such as mycophenolate or azathioprine) in preventing deterioration after steroid

178 e support the contention that treatment with azathioprine increases the risk of SCC in OTRs.

179 tivity syndrome and review the literature on azathioprine-induced eruptions with features of Sweet sy

180 se (TPMT) polymorphism (a key determinant of azathioprine-induced myelotoxicity) by using TPMT enzyme

181 nfliximab, the combination of infliximab and azathioprine (infliximab + azathioprine), adalimumab, an

182 ment of cultured pancreatic tumor cells with azathioprine inhibited Vav1-dependent invasive cell migr

183 Azathioprine initiation preceded admission with a sore t

184 Azathioprine interference in nucleic acid metabolism may

185 ethyltransferase deficiency does not predict azathioprine intolerance.

186 We aimed to investigate whether use of azathioprine is associated with the risk of acute pancre

187 Budesonide in combination with azathioprine is effective frontline therapy, and therape

188 Budesonide in combination with azathioprine is effective frontline therapy.

189 Azathioprine is used as a first-line treatment to preven

190 th African American ethnicity and the use of azathioprine; it appears to exert an impact on damage bu

191 The antimetabolites, such as methotrexate, azathioprine, leflunomide, and mycophenolate, are often

192 higher in recipients prescribed cyclosporine/azathioprine maintenance therapy (aIRR 1.79, 95% CI 1.09

193 r time after transplantation but higher with azathioprine maintenance therapy (IRR=1.35, 95% CI 1.03-

194 let radiation exposure, and cyclosporine and azathioprine may contribute as photosensitizing or DNA d

195 Thiopurines (azathioprine, mercaptopurine, thioguanine) and methotrex

196 ks of treatment with infliximab monotherapy, azathioprine monotherapy, or the 2 drugs combined in tum

197 to significantly better mucosal healing than azathioprine monotherapy.

198 include the chemotherapies cyclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

199 round treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate.

200 and selenium) and immunosuppression regimes (azathioprine, mycophenolate mofetil, calcineurin inhibit

201 h NMO and NMO spectrum disorder treated with azathioprine, mycophenolate, and/or rituximab at the May

202 The 10 cases were treated with azathioprine, mycophenolic acid, methotrexate, or inflix

203 A total of 156 patients were assigned to azathioprine (n = 80) or mycophenolate mofetil (n = 76)

204 te optimum topical therapy to treatment with azathioprine (n=42) or placebo (n=21) for 12 weeks.

205 In PANTHER-IPF, exposure to prednisone/azathioprine/N-acetylcysteine was associated with a high

206 day(-1), n = 65) or conventional management (azathioprine only in cases of corticosteroid dependency,

207 e (IBD) activity among patients treated with azathioprine or 6-mercaptopurine (6-MP).

208 g the immunosuppressant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine

209 ived 50% of the standard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygo

210 nticancer and immunosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acu

211 4% of patients treated with the thiopurines azathioprine or mercaptopurine.

212 patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains h

213 Treatment with azathioprine or mycophenolate did not affect PV or PI in

214 Cyclosporine was combined with azathioprine or mycophenolate in cases unresponsive to o

215 aim was to determine whether rituximab with azathioprine or mycophenolate mofetil improves the high-

216 nce immunosuppression included cyclosporine, azathioprine or mycophenolate mofetil, and prednisone.

217 Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to co

218 Secondary immunosuppressants (azathioprine or mycophenolate) and steroids remained unc

219 lation, which included all patients who used azathioprine or tocilizumab as monotherapy.

220 for patients receiving weekly adalimumab and azathioprine or weekly adalimumab alone if failure crite

221 (OR, 2.5; 95% CrI, 1.4-4.6) and infliximab + azathioprine (OR, 2.6; 95% CrI, 1.3-6.0).

222 ab (OR, 1.6; 95% CrI, 1.0-2.5), infliximab + azathioprine (OR, 3.0; 95% CrI, 1.7-5.5) for maintenance

223 i-tumor necrosis factor agents, infliximab + azathioprine (OR, 3.1; 95% CrI, 1.4-7.7) and adalimumab

224 ion at week 26 of treatment with infliximab, azathioprine, or both.

225 ) than RTRs who used cyclosporine, steroids, azathioprine, or had Medicare (P<0.05).

226 aced by oral prednisolone with cyclosporine, azathioprine, or mycophenolate as steroid-sparing agents

227 = 0.001) and 65% (13/20) in patients taking azathioprine (p = 0.14).

228 ab (P = .295) and 36.8% (28 of 76) receiving azathioprine (P =.001).

229 n of chronic GVHD therapy (P < .001); use of azathioprine, particularly when combined with cyclospori

230 ce therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combination with Gr

231 ): cyclophosphamide for 3 months followed by azathioprine plus oral prednisolone).

232 sis in one sister was made after a suspected azathioprine-precipitated acute illness.

233 drug immunosuppressive regimen (cyclosporine+azathioprine+prednisone) affects the islet engraftment p

234 lacement was first accomplished in 1967 with azathioprine, prednisone, and antilymphoid globulin.

235 interval: 1.15, 1.74), whereas former use of azathioprine (rate ratio = 1.02, 95% confidence interval

236 Due to the potential for anaphylaxis with azathioprine rechallenge, a better term for a Sweetlike

237 Azathioprine reduced the relapse rate by 72.1% but had a

238 tarium, replacing the antimetabolite prodrug azathioprine, reports have associated certain forms of w

239 s associated with drugs, such as dapsone and azathioprine, respectively.

240 monthly corticosteroid pulses (temporary) or azathioprine, respectively.

241 ignificant heterogeneity between studies for azathioprine risk estimates and the outcomes of SCC, BCC

242 We aimed to resolve the issue of azathioprine's carcinogenicity by conducting a systemati

243 mab, mycophenolate, and, to a lesser degree, azathioprine significantly reduces relapse rates in NMO

244 Azathioprine sodium use was observed more frequently in

245 ditioning cytoreduction with hydroxyurea and azathioprine starting at -45 days pretransplant, and flu

246 Patients were randomly assigned to azathioprine (starting at 2 mg/kg/d) or mycophenolate mo

247 However, the addition of azathioprine substantially reduced the risk of HCMV repl

248 ted with 6-thioguanine (6-TG, a DNA-embedded azathioprine surrogate), the fluoroquinolones ciprofloxa

249 ors before retransplantation, treatment with azathioprine, T cell-depleting antibodies, and delayed r

250 drawal due to adverse events was higher with azathioprine than with mycophenolate mofetil (39.6% vs.

251 The immunosuppressant azathioprine, the fluoroquinolone antibiotics and vemura

252 h severe chronic GVHD were also treated with azathioprine, the independent effects of these factors c

253 rative efficacy and safety of infliximab and azathioprine therapy alone or in combination for ulcerat

254 is the first reported case of LYG related to azathioprine therapy in Crohn disease.

255 an with colonic Crohn disease on maintenance azathioprine therapy presented with right upper quadrant

256 study of adults with Crohn's disease, early azathioprine therapy was no more effective than placebo

257 th inflammatory bowel diseases and long-term azathioprine therapy.

258 Upon treatment with the immunosuppressant azathioprine there was significant resolution of the les

259 Azathioprine toxicities cannot be predicted.

260 The DNA of azathioprine-treated patients contains 6-thioguanine (6-

261 ilizumab-treated patients and 49 (83%) of 59 azathioprine-treated patients.

262 No significant associations between azathioprine treatment and BCC (0.96, 95% CI 0.66-1.40)

263 Furthermore, azathioprine treatment decreased metastasis in both xeno

264 dial effusion occurred with sirolimus versus azathioprine treatment in a cardiac transplantation tria

265 Azathioprine treatment was associated with increased CIM

266 Azathioprine treatment was discontinued resulting in res

267 e, higher lipoprotein(a) level, proteinuria, azathioprine treatment, and prednisone dose.

268 verall and other skin cancers in relation to azathioprine treatment.

269 l lines and tumors were largely resistant to azathioprine treatment.

270 ths 6, 12, and 18 after study entry or daily azathioprine until month 22.

271 In multivariable modeling, both azathioprine use (P=0.005 for the mean-mean model and P=

272 Episodes of incident azathioprine use and no use of any thiopurine were match

273 Data on azathioprine use was also collected.

274 Azathioprine use was associated with an increased risk o

275 In conclusion, azathioprine use was associated with an increased risk o

276 Azathioprine use was associated with an increased risk o

277 In subgroup analyses, azathioprine use was associated with increased risk of l

278 that prolonged immunosuppressive therapy and azathioprine use were also significant risk factors for

279 Disease duration, lymphocyte count, and azathioprine use were shown to be significant independen

280 After adjusting for donor age and azathioprine use, homozygous TLR2 mutation (RR 5.20 [1.6

281 tment (within 6 months after diagnosis) with azathioprine versus conventional management of patients

282 ermore, nonbiologic combination therapy with azathioprine was associated with a higher DR owing to AD

283 Azathioprine was associated with a lower risk of myeloma

284 Use of azathioprine was associated with an increased risk of ac

285 in survival outcome occurred (Theme IV) when azathioprine was replaced by cyclosporine (1979), which

286 Generally, azathioprine was well tolerated, although two individual

287 The commercial drug Imuran (azathioprine) was synthesized as an example, and its pre

288 The purine analogue azathioprine, well known for its function as an anti-inf

289 Mycophenolate and azathioprine were associated with a lower risk of PTLD (

290 lts, a European trial concluded that MMF and azathioprine were equivalent in the ability to prevent r

291 te to severe UC treated with infliximab plus azathioprine were more likely to achieve corticosteroid-

292 Adalimumab, infliximab, and infliximab + azathioprine were superior to azathioprine/6-mercaptopur

293 Adalimumab and infliximab + azathioprine were superior to certolizumab: adalimumab (

294 Some localized melanomas may result from azathioprine, which acts synergistically with UV radiati

295 olitis responded well to corticosteroids and azathioprine, which is supportive of their immune pathog

296 compared with regimens containing MMF/MPA or azathioprine with CNI.

297 Mycophenolate mofetil was superior to azathioprine with respect to the primary end point, time

298 agnosis is on a low dose of prednisolone and azathioprine, with no signs of relapse.

299 lts from a clinical trial, administration of azathioprine within 6 months of diagnosis of CD was no m

300 ed after immunosuppression with steroids and azathioprine without administration of calcineurin inhib